Clinical Report: Sustained Response to Combined BRAF and MEK Inhibition in Colorectal Cancer with BRAF Mutation

Overview

This case study presents a 60-year-old male patient with BRAF V600E-mutant metastatic colorectal cancer who achieved a sustained response to a combination of the BRAF inhibitor vermurafenib and the MEK inhibitor cobimetinib. The patient maintained stable disease for nearly four years.

Background

BRAF V600E mutations in metastatic colorectal cancer (mCRC) are associated with poor prognosis and limited treatment options. The combination of BRAF inhibitors with MEK inhibitors has been explored in clinical trials.

Data Highlights

No numerical data or trial data provided in the article.

Key Findings

• The patient experienced a prolonged progression-free survival of nearly four years on a MEKi-based regimen.
• First-line treatment with FOLFOXIRI plus bevacizumab led to a partial response before the introduction of targeted therapy.
• Previous trials have shown limited efficacy of BRAF inhibitors as single agents, necessitating combination therapies.

Clinical Implications

This case suggests that MEK inhibitors may play a critical role in the treatment of BRAF V600E-mutant mCRC, warranting further investigation. Clinicians should consider genomic profiling to guide treatment decisions and explore combination therapies for improved patient outcomes.

Conclusion

The sustained response observed in this case highlights the potential of MEK inhibitors in managing BRAF-mutant mCRC and calls for further research into their clinical application.

Related Resources & Content

1. The ASCO Post, Treating BRAF V600E Colorectal Cancer May Require Concomitant BRAF and PI3K/mTOR Inhibition
2. The ASCO Post, Experimental Regimen Demonstrates Benefit in BRAF V600E–Mutant Metastatic Colorectal Cancer
3. The ASCO Post, Combination of BRAF and MEK Inhibitors Paves Way for Phase III Studies in BRAF-mutated Metastatic Melanoma
4. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
5. FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation
6. the asco post — Triplet Regimen Demonstrates Benefit in BRAF V600E–Mutant Metastatic Colorectal Cancer
7. Targeted Drug Trio for Colorectal Cancer with BRAF Mutations - NCI
8. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
9. FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation | FDA
10. Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer | New England Journal of Medicine
11. Targeted doublet therapy with encorafenib and cetuximab for BRAF V600E-mutant metastatic colorectal cancer: A systematic review and meta-analysis - ScienceDirect